SEC Company Response from Outlook Therapeutics, (OTLK) — Mar 20, 2017
Outlook Therapeutics, Inc.
Date: March 20, 2017 · CIK: 0001649989 · Accession: 0001571049-17-002634
AI Filing Summary & Sentiment
File numbers found in text: 333-216610
Letter
Re: Oncobiologics, Inc.
March 20, 2017
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Ms. Suzanne Hayes
Registration Statement on Form S-1
Filed March 10, 2017
File No. 333-216610
Acceleration Request
Requested Date: Wednesday, March 22, 2017
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Oncobiologics, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 (File No. 333-216610) to become effective on March 22, 2017, at 4:00 P.M., Eastern Time, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff of the Commission (the “Staff”). The Registrant hereby authorizes each of Yvan-Claude Pierre and Marianne Sarrazin of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
In connection with this request, the Registrant acknowledges that:
· should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
7 Clarke Drive, Cranbury, NJ 08512 (609) 619-3990
Very truly yours,
Oncobiologics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
March 20, 2017
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Ms. Suzanne Hayes
Re: Oncobiologics, Inc.
Registration Statement on Form S-1
Filed March 10, 2017
File No. 333-216610
Acceleration Request
Requested Date: Wednesday,
March 22, 2017
Requested Time: 4:00
P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule
461 under the Securities Act of 1933, as amended, Oncobiologics, Inc. (the “Registrant”) hereby requests
that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause
the above-referenced Registration Statement on Form S-1 (File No. 333-216610) to become effective on March 22, 2017, at 4:00 P.M.,
Eastern Time, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via
telephone call to the staff of the Commission (the “Staff”). The Registrant hereby authorizes each of
Yvan-Claude Pierre and Marianne Sarrazin of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
In connection with this
request, the Registrant acknowledges that:
· should the Commission or the Staff, acting
pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with
respect to the filing;
· the action of the Commission or the Staff,
acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility
for the adequacy and accuracy of the disclosure in the filing; and
· the Registrant may not assert Staff comments
and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal
securities laws of the United States.
7 Clarke Drive, Cranbury, NJ 08512
(609) 619-3990
Very truly yours,
Oncobiologics, Inc.
By:
/s/ Lawrence A. Kenyon
Lawrence A. Kenyon
Chief Financial Officer
cc: Pankaj Mohan, Ph.D., Oncobiologics, Inc.
Yvan-Claude Pierre, Cooley LLP
Marianne Sarrazin, Cooley LLP
Pia Kaur, Cooley LLP